VISTA

Exagen Announces Campaign for Lupus Awareness Month

Retrieved on: 
Monday, May 6, 2024
Education, Learning, Lupus, Social media, Risk, Tissue, Partnership, Research, Disease, Patient, Diagnosis, SLE, Quality of life, Human body, Nursing

CARLSBAD, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a campaign focusing on providers, patients and partnership activities that enhance the impactful work being done to help those suffering from Systemic Lupus Erythematosus (SLE).

Key Points: 
  • CARLSBAD, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a campaign focusing on providers, patients and partnership activities that enhance the impactful work being done to help those suffering from Systemic Lupus Erythematosus (SLE).
  • Lupus Awareness Month occurs every May and is an important platform for lupus-focused organizations to educate and advocate for those affected by this complex condition.
  • Lupus is a disease that AVISE® testing is specially equipped to help with and today marks the start of a month-long awareness campaign.
  • Join us in our efforts to amplify this condition throughout Lupus Awareness Month and support those struggling with this relentless disease,” said John Aballi, President and CEO of Exagen.

Exagen Inc. Announces Changes to the Board of Directors

Retrieved on: 
Friday, April 26, 2024
University, Commoner, Rady Children's Hospital, Hospital, Champaign–Urbana metropolitan area, Churchill College, Cambridge, XGN, Privacy, SVP, Genetic distance, Growth, Postdoctoral researcher, Management

CARLSBAD, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced changes to the Board of Directors.

Key Points: 
  • CARLSBAD, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced changes to the Board of Directors.
  • Exagen is pleased to announce Scott Kahn, Ph.D. is joining the Board as a Class I Director.
  • “First, I want to thank Brian Birk, Beto Pallares, Ph.D. and Wendy Johnson for their years of commitment and service to the Exagen Board of Directors.
  • To ensure we are well-equipped to grow with these changes, we have appointed Dr. Kahn to our Board of Directors.

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results

Retrieved on: 
Monday, March 18, 2024
Health, Interest, Webcast, Patient, Research, CTD, ASP, Depreciation, GAAP, Income tax, Total, Beauty salon

Net loss of $23.7 million for the full-year 2023 and $5.6 million for the fourth quarter of 2023.

Key Points: 
  • Net loss of $23.7 million for the full-year 2023 and $5.6 million for the fourth quarter of 2023.
  • Adjusted EBITDA of $(17.1) million for the full-year 2023 and $(3.9) million in the fourth quarter of 2023.
  • Total gross margin was 59.2% in the fourth quarter of 2023 compared to 50.9% in the fourth quarter of 2022.
  • Operating expenses were $18.9 million in the fourth quarter of 2023, compared to $27.3 million in the fourth quarter of 2022.

Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Retrieved on: 
Friday, March 8, 2024
XGN, Medtech

CARLSBAD, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum, which takes place virtually March 19-20, 2024.

Key Points: 
  • CARLSBAD, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum, which takes place virtually March 19-20, 2024.
  • John Aballi, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Exagen’s Chief Financial Officer, will participate in one-on-one meetings with investors and a fireside chat on Wednesday, March 20, at 1:30 PM ET.

Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024

Retrieved on: 
Thursday, March 7, 2024
Interest, XGN, Webcast, Cryptocurrency

CARLSBAD, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31, 2023, before the market opens on Monday, March 18, 2024.

Key Points: 
  • CARLSBAD, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31, 2023, before the market opens on Monday, March 18, 2024.
  • John Aballi, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company’s results at 8:30 AM ET (5:30 AM PT).
  • A replay of the conference call will be available until Monday, April 1, 2024, at 11:59 PM ET (8:59 PM PT).
  • Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately one hour after the call concludes.

Exagen Inc. to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Retrieved on: 
Tuesday, January 30, 2024
Digital health, Conference, XGN

CARLSBAD, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 13-14, 2024 in Snowbird, Utah.

Key Points: 
  • CARLSBAD, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 13-14, 2024 in Snowbird, Utah.
  • John Aballi, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Exagen’s Chief Financial Officer, will be participating in one-on-one meetings with investors during the event; meetings can be requested through BTIG.

Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance

Retrieved on: 
Sunday, January 7, 2024
ASP, Bank statement, Depreciation, XGN, Net, CTD, GAAP, Cryptocurrency

CARLSBAD, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announces select preliminary unaudited financial results for the full year ended December 31, 2023, and reaffirms its full-year 2023 financial guidance.

Key Points: 
  • CARLSBAD, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announces select preliminary unaudited financial results for the full year ended December 31, 2023, and reaffirms its full-year 2023 financial guidance.
  • The company reaffirms its full-year 2023 total revenue guidance of at least $50 million and full-year 2023 non-GAAP adjusted EBITDA guidance of approximately negative $20 million.
  • The company is providing the above preliminary financial information and results of operations as of and for the year ended December 31, 2023, based on currently available information.
  • As a result, the company’s final results may vary from the preliminary results presented above.

Exagen Inc. Reports Strong Third Quarter 2023 Results

Retrieved on: 
Monday, November 13, 2023
Johns Hopkins University, Webcast, EBITDA, Interest, SAN, LLP, Bank statement, BDO, Net, Depreciation, ASP, XGN, GAAP, Lupus nephritis, Growth, Medicare, Biomarker, CTD, Coal, Bookkeeping, Video game, Bank, Lipotriches exagens

SAN DIEGO, California, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2023.

Key Points: 
  • SAN DIEGO, California, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2023.
  • Revenue was $13.4 million for the third quarter of 2023, compared with $14.7 million in the third quarter of 2022 and $14.1 million in the second quarter of 2023.
  • Gross margin was 57.4% in the third quarter of 2023, compared to 58.7% in the second quarter of 2023 and 59.2% in the third quarter of 2022.
  • A conference call to review third quarter 2023 financial results and to provide a business update is scheduled for today, November 13, 2023, at 4:30 PM Eastern Time (1:30 PM Pacific Time).

Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers

Retrieved on: 
Thursday, November 9, 2023
Johns Hopkins University, Nephritis, Biomarker, Lipotriches exagens, Patient, SAN, Lupus nephritis, MPH, Pharmaceutical industry, MD

SAN DIEGO, California, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Johns Hopkins University jointly announced today the execution of an exclusive license agreement.

Key Points: 
  • SAN DIEGO, California, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Johns Hopkins University jointly announced today the execution of an exclusive license agreement.
  • Exagen will focus on the development of novel patented biomarkers for therapeutic management of patients with lupus nephritis.
  • Exagen intends to develop the novel biomarkers into assays to aid diagnostic and treatment decisions by providing unique clinical insight into a specific patient’s lupus nephritis in a non-invasive manner.
  • “We are very excited to accelerate the development of these highly innovative biomarkers for lupus nephritis patient management.

Exagen Inc. to Participate in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Retrieved on: 
Thursday, November 2, 2023
The Westin New York Grand Central Hotel, Diagnosis, Interest, Digital health, SAN, Retail

SAN DIEGO, California, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, which takes place November 16th, 2023, at the Westin New York Grand Central Hotel in New York City.

Key Points: 
  • SAN DIEGO, California, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, which takes place November 16th, 2023, at the Westin New York Grand Central Hotel in New York City.
  • John Aballi, Exagen’s President and Chief Executive Officer and Kamal Adawi, Exagen’s Chief Financial Officer, will present at 9:30 AM ET.
  • Interested parties may access the webcast of the presentation using a link on Exagen’s website at https://investors.exagen.com/events .